You've stopped losing weight on Wegovy — what's actually going on

Six months in, the scales haven't moved in weeks

You started Wegovy, noticed real change in the first few months, and then, nothing. The number on the scales sat still. This is the point many people reach and quietly wonder whether they have somehow become immune to the medicine, or whether Wegovy has simply run out of effect for them.

What is more likely is metabolic adaptation. As your body reaches a lower weight, it becomes more efficient at conserving energy: your basal metabolic rate falls, you burn fewer calories at rest, and the deficit that drove earlier loss gradually narrows. This happens with every form of weight reduction, not just medication. It is biology, not failure. The NHS patient information for semaglutide notes that weight loss is expected to be greatest in the earlier months of treatment, and that continued treatment is about sustaining that lower weight as well as achieving further reduction.

There is also a question of where you are in your titration. Semaglutide's maintenance pathway runs from a 0.25 mg starting dose up to 2.4 mg, titrated roughly every four weeks. If you are still at an intermediate dose, the clinical picture may look different once you reach the highest tolerated level. That conversation belongs with your prescriber, not a forum.

Appetite returning is a signal worth investigating, not ignoring

A question our prescribers hear most weeks: "I feel hungry again, does that mean Wegovy has stopped working?" It can mean several things. Some people find appetite suppression is less pronounced once they have been on a stable dose for a long time. Others find that eating patterns have gradually drifted back towards higher-calorie choices, not through lack of effort, but because the initial intensity of appetite suppression softens.

It is also worth considering the practical side. Semaglutide must be injected once weekly on a consistent schedule; delayed injections, missed doses, or changes to injection technique can affect how consistently the medicine is absorbed. Storage matters too, a pen that has been left out of the fridge beyond the window stated in the Patient Information Leaflet may be less effective. If any of this is relevant, the leaflet and your prescriber are the right first stops, not dose-chasing on your own.

If you suspect Wegovy simply isn't working as it used to, a structured review of the evidence (including your weight log, dose history, and what has changed in your routine) gives a prescriber what they need to advise you properly. There is guidance on what to consider if progress has stalled entirely at our page on Wegovy no longer working.

What a clinical review can actually address

A plateau is not automatically a reason to stop treatment. NICE's appraisal of semaglutide (TA875) suggests reviewing continuation if less than 5% weight loss has occurred after six months on the maintenance dose, but this applies to a specific clinical threshold, not to a short plateau mid-titration or to someone who has already lost significant weight and is now maintaining it. The distinction matters.

What a prescriber can do: assess whether you are on the highest tolerated dose, look at whether lifestyle factors have shifted, consider whether a different treatment approach might better suit your situation, and help you understand whether you are in a true plateau or a maintenance phase. If you are specifically on Wegovy but not losing weight, that page looks at the reasons this happens and what steps are worth considering. For context on how other people on semaglutide experience similar pauses, this page looks at the broader semaglutide weight-loss plateau question in more detail.

If you started Wegovy privately and want your progress reviewed, a free consultation with one of our prescribers is the place to start. At nume, a real clinician reads your answers and your history (not software) and responds the same day. The cost and what is included in a private treatment review is covered on our weight-loss treatment overview.

Things that genuinely affect whether loss continues

A few factors consistently come up in clinical practice when a patient's progress has flattened. Protein intake is one: appetite suppression sometimes leads people to eat very little overall, and without enough protein, muscle mass can fall alongside fat. Less muscle means a lower metabolic rate, which compounds the adaptation already happening. Strength-based activity helps preserve muscle and keeps metabolism from dropping as sharply.

Calorie creep is another. The foods that felt unappealing at peak appetite suppression may feel manageable again at a stable dose. Liquid calories (drinks, sauces, alcohol) are easy to underestimate and are not meaningfully affected by gastric slowing the way solid food is.

Sleep and stress both influence the hormones that drive hunger. Neither is under full conscious control, but both are worth discussing with a clinician if you notice your appetite has come back more strongly. For people wondering whether this experience is a sign they should switch medicine or approach, our page on not losing weight on semaglutide explores why the medicine can underperform and what a prescriber is likely to consider. For people wondering whether this experience is a sign they should switch medicine or approach, our page on seeing no loss at all on Wegovy covers a different but related scenario. And if you are weighing up how Wegovy compares to other options, our Wegovy overview sets out the clinical picture plainly.